Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H4N2S2 |
Molecular Weight | 192.261 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
S=C=NC1=CC=C(C=C1)N=C=S
InChI
InChIKey=OMWQUXGVXQELIX-UHFFFAOYSA-N
InChI=1S/C8H4N2S2/c11-5-9-7-1-2-8(4-3-7)10-6-12/h1-4H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/769080Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/769078 | https://www.ncbi.nlm.nih.gov/pubmed/955553 | https://www.ncbi.nlm.nih.gov/pubmed/769062 | https://www.ncbi.nlm.nih.gov/pubmed/26639764
Sources: https://www.ncbi.nlm.nih.gov/pubmed/769080
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/769078 | https://www.ncbi.nlm.nih.gov/pubmed/955553 | https://www.ncbi.nlm.nih.gov/pubmed/769062 | https://www.ncbi.nlm.nih.gov/pubmed/26639764
Bitoscanate is a tasteless, odorless, colorless, needle-like crystalline solid material prepared from mustard powder acid and used as an anthelmintic against nematodes, especially hookworms (Necator sp.) and Ancylostoma duodenale. Side effects reported with therapeutic use have been nausea, vomiting, diarrhea, abdominal pain or discomfort, loss of appetite, dizziness or giddiness, vertigo, weakness, headache, and an itching sensation over the body. Such side effects have most often been mild and required no treatment. Bitoscanate is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
C-terminal sequence analysis of peptides using triphenylgermanyl isothiocyanate. | 2002 Mar 1 |
|
Molecular printboards: monolayers of beta-cyclodextrins on silicon oxide surfaces. | 2004 Jun 22 |
|
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. | 2004 May 1 |
|
[Oligonucleotide microarray preparation using enhanced poly-L-lysine glass slides]. | 2004 Nov |
|
Suppressive effect of 1,4-phenylene diisothiocyanate on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. | 2005 Nov 20 |
|
A Novel Label-Free Optical Biosensor Using Synthetic Oligonucleotides from E. coli O157:H7: Elementary Sensitivity Tests. | 2009 |
|
Surface immobilisation of antibody on cyclic olefin copolymer for sandwich immunoassay. | 2009 Apr 15 |
|
The specific isolation of C-terminal peptides of proteins through a transamination reaction and its advantage for introducing functional groups into the peptide. | 2009 Mar |
|
Immobilization of trypsin onto 1,4-diisothiocyanatobenzene-activated porous glass for microreactor-based peptide mapping by capillary electrophoresis: effect of calcium ions on the immobilization procedure. | 2010 Mar 24 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/769062
2X 50 mg (50 mg at. 12-hourly intervals)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26639764
The antiproliferative activity of Bitoscanate was evaluated on the human colon adenocarcinoma cell line (LoVo) and the doxorubicin-resistant human colon adenocarcinoma cell line (LoVo/DX) by means of the sulforhodamine B (SRB) assay. The impact of the compounds under study on cells viability is presented as a 50% growth inhibitory concentration (IC50) with doxorubicin used as reference. Bitoscanate shows moderate antiproliferative activity with IC50 = 9.41 mkM (LoVo) and 11.6 mkM (LoVo/DX)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C250
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2397
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104676
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
223-741-3
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
DTXSID3046532
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
3033
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
6435
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
6D1R3P86GX
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
100000086324
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
SUB05861MIG
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
19958
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
C032582
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
758884
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
C72149
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
BITOSCANATE
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
4044-65-9
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | |||
|
m2579
Created by
admin on Sat Dec 16 16:52:37 GMT 2023 , Edited by admin on Sat Dec 16 16:52:37 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY